Indeed, the thiazolidinedione class of drugs, the PPARγ full agonists, has a long history of use in treating Type 2 diabetes mellitus for its insulin sensitizing effects, though multiple side effects exist including obesity, water retention, increased risk of cardiovascular diseases and bone fractions. This evidence concerns the gene PPARG and cardiovascular disorder.